
Engage the Experts
pDNA, mRNA, and LNP Solutions from Research to Commercialization
Wacker Biotech is your CDMO partner for the entire manufacturing chain of plasmid DNA (pDNA) and messenger RNA (mRNA) to lipid nanoparticle (LNP) formulations. We leverage our global team of development, process engineering, and manufacturing experts and a network of state-of-the-art facilities to accelerate our partners’ programs from research phase to the market.
Contact usYou benefit from our decades of experience in complex protein-based therapeutics, vaccines, and specialty chemicals sectors, including partnering with the German government to respond to the Covid-19 pandemic.
We invite you to explore this page and discover Wacker Biotech’s end-to-end services, including pDNA, mRNA and LNP capabilities and insights from our scientific leadership.
Insights from Our Experts
Overcoming pDNA Supply Challenges for mRNA Manufacturing
Mack Kuo, Associate Director of Process Development, Wacker Biotech US, explores the skyrocketing demand for pDNA as mRNA and gene therapy candidates continue to progress from preclinical to early- and late-stage clinical studies. Learn how experts are navigating obstacles such as sourcing challenges, quality issues, scaling difficulties, and lack of standardization. Download the file from the box below.
Navigating mRNA Manufacturing with Flexibility and Innovation
Michael Van der Horst, Head of BioProcess Development, Wacker Biotech, shares how Wacker Biotech is meeting the challenge of the complex, multistep processes involved in mRNA–LNP manufacture. Gain insights into how true end-to-end CDMOs can help coordinate raw material supply, scaling, and aligning steps across vendors. Download the file from the box below.
Technology Advances Needed to Drive Future mRNA Growth
Hagen Richter, Head of Nucleic Acids Research, Wacker Biotech, discusses how applications for mRNA are evolving beyond vaccines to therapeutics that treat large populations and personalized therapies tailored to individual patients. Richter also explores the opportunity for innovation in mRNA therapeutic manufacturing, such as continuous strategies and alternatives to pDNA, in vitro transcription, and LNP delivery. Download the file from the box below.

Engage the Experts in Nucleic Acid Therapies
Founded in 1914, WACKER was a key player in forging specialty chemistry advancements throughout the 20th century. In the 21st century, Wacker Biotech has leveraged our wealth of resources, scale, and deep expertise to help advance tomorrow’s life-saving therapies. In close collaboration with universities and research institutions, WACKER’s corporate R&D team of over 200 researchers continuously develops new production platforms and technologies for all types of biopharmaceuticals, including pDNA, mRNA and LNPs. Competitive, outstanding solutions are our trademarks.
Powered by our network of global facilities and commitment to excellence, Wacker Biotech continues to advance nucleic acid therapies, proving highly effective for treating, curing, and preventing diseases for patients worldwide.
Take advantage of this opportunity to shape the future of mRNA therapeutics. Contact us, your reliable mRNA CDMO partner, today for your next mRNA project.
Contact us